Paragraph IV Certifications: How Generic Drug Makers Legally Challenge Brand-Name Patents
Paragraph IV certifications allow generic drug makers to legally challenge brand-name patents before launch. This Hatch-Waxman Act mechanism has saved over $1.7 trillion since 1984 by accelerating generic entry and rewarding the first challenger with 180 days of exclusivity.
Continue reading...